文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

高剂量阿那白滞素治疗婴儿难治性川崎病所致巨噬细胞活化综合征。

High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.

作者信息

Lind-Holst Marie, Hartling Ulla Birgitte, Christensen Anne Estmann

机构信息

Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.

出版信息

BMJ Case Rep. 2019 Aug 4;12(8):e229708. doi: 10.1136/bcr-2019-229708.


DOI:10.1136/bcr-2019-229708
PMID:31383678
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6685371/
Abstract

We report a 12-week-old boy presenting with incomplete refractory Kawasaki disease (KD) complicated with macrophage activation syndrome (MAS). The infant presented with cerebral irritability, pain, tachypnoea and vomiting for 10 days. He did not fulfil any of the classic diagnostic criteria for KD. Pericardial effusion on echocardiography in addition to severe dilatation of the coronary arteries in combination with leucocytosis and raised acute phase reactants led to the diagnosis of incomplete KD. Treatment with intravenous immunoglobulin and aspirin was initiated but without any response. The condition was subsequently refractory to additional treatment with infliximab and high-dose methylprednisolone. His condition worsened, fulfilling the criteria for MAS. High-dose anakinra was initiated, and remission of the inflammation was achieved.

摘要

我们报告了一名12周大的男孩,患有不完全性难治性川崎病(KD)并伴有巨噬细胞活化综合征(MAS)。该婴儿出现脑激惹、疼痛、呼吸急促和呕吐10天。他不符合任何KD的经典诊断标准。超声心动图显示有心包积液,同时冠状动脉严重扩张,伴有白细胞增多和急性期反应物升高,从而诊断为不完全性KD。开始静脉注射免疫球蛋白和阿司匹林治疗,但无任何反应。随后,英夫利昔单抗和大剂量甲泼尼龙的额外治疗也无效。他的病情恶化,符合MAS的标准。开始使用大剂量阿那白滞素,炎症得以缓解。

相似文献

[1]
High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.

BMJ Case Rep. 2019-8-4

[2]
High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.

Pediatr Rheumatol Online J. 2014-7-11

[3]
Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm.

Cardiol Young. 2018-5

[4]
Kawasaki disease shock syndrome complicated with macrophage activation syndrome in a 5-month old boy: A case report.

Medicine (Baltimore). 2019-1

[5]
Anakinra and hepatotoxicity in pediatric rheumatology: a case series.

Pediatr Rheumatol Online J. 2023-10-6

[6]
Macrophage activation syndrome in Kawasaki disease.

Indian Pediatr. 2014-2

[7]
Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.

Rheumatology (Oxford). 2021-7-1

[8]
Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches.

World J Pediatr. 2020-12

[9]
Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.

J Clin Rheumatol. 2011-1

[10]
Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.

Intern Med J. 2012-12

引用本文的文献

[1]
Macrophage Activation Syndrome in Kawasaki Disease: Insights from a Systematic Literature Review on Diagnosis, Clinical Features, and Treatment.

Children (Basel). 2025-3-11

[2]
Off-Label Use of Anakinra in Inflammatory Conditions in Neonates and Infants Up to 3 Months of Age: A Case Series and a Review of the Literature.

Paediatr Drugs. 2025-5

[3]
Kawasaki Disease-Associated Cytokine Storm Syndrome.

Adv Exp Med Biol. 2024

[4]
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.

Exp Mol Med. 2024-3

[5]
[Clinical features of Kawasaki disease complicated by macrophage activation syndrome: an analysis of 27 cases].

Zhongguo Dang Dai Er Ke Za Zhi. 2023-6-15

[6]
Inflammatory responses in SARS-CoV-2 associated Multisystem Inflammatory Syndrome and Kawasaki Disease in children: An observational study.

PLoS One. 2022

[7]
Kawasaki Disease and Coronary Artery Involvement: A Narrative Review.

Cureus. 2022-8-24

[8]
NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.

Int J Physiol Pathophysiol Pharmacol. 2022-6-15

[9]
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3.

Arthritis Rheumatol. 2022-4

[10]
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?

Curr Res Pharmacol Drug Discov. 2021

本文引用的文献

[1]
The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series.

Autoimmun Rev. 2018-6-6

[2]
High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease.

J Pediatr. 2017-6

[3]
IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease.

Front Pharmacol. 2017-3-28

[4]
A child with resistant Kawasaki disease successfully treated with anakinra: a case report.

BMC Pediatr. 2017-4-8

[5]
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Circulation. 2017-3-29

[6]
Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Arthritis Rheumatol. 2017-2

[7]
Should refractory Kawasaki disease be considered occult macrophage activation syndrome?

Semin Arthritis Rheum. 2017-2

[8]
Clinical Characteristics of Kawasaki Disease in Infants Younger than Six Months: A Single-Center Study.

Korean Circ J. 2016-7

[9]
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Ann Rheum Dis. 2016-3

[10]
Macrophage Activation Syndrome.

Hematol Oncol Clin North Am. 2015-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索